Bharat Biotech Ramps Up Covaxin Production By Additional 200 Million

Bhubaneswar: Hyderabad-based Bharat Biotech International Ltd on Monday announced quick ramping up of its additional manufacturing capacities for its Indigenous COVID-19 vaccine- Covaxin at CHIRON BEHRING Vaccines, a wholly owned subsidiary of Bharat Biotech, in Ankleshwar, Gujarat.

The vaccine manufacturing company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. 

Also Read

2nd Covishield Vaccine Dose: Already Booked Online Appointments To Remain Valid

Read More

Over 20 Cr COVID19 Vaccine Doses Given To States/Uts Free Of Cost

Read More

India Will Have 51.6 Crore COVID19 Vaccine Doses By End Of July: Union Health Min

Read More

The product availability at the subsidiary in Gujarat will commence from Q4 2021. 

Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses. Adding Chiron Behring to this line of high containment BSL rated GMP facilities that are required to manufacture Covaxin. This will scale up the volume of vaccine manufacturing to 1 billion doses per annum. 

Its own established campuses are specialized for manufacturing inactivated viral vaccines under the highest level of biosafety, said the company in a release.
 

OTV News is now on Whatsapp

Join and get latest news update delivered to you via whatsapp

Join Now